Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease
Open Access
- 28 June 2004
- Vol. 101 (3), 558-566
- https://doi.org/10.1002/cncr.20405
Abstract
BACKGROUND Venous thromboembolic disease (VTD) is a recently recognized complication of thalidomide in combination therapy for patients with multiple myeloma (MM). The authors assessed the frequency of VTD and its risk factors in 612 consecutive patients with plasma cell dyscrasia (PCD) who were evaluated and followed from 1991 to 2001. METHODS In the current study, 404 patients were diagnosed with multiple myeloma (MM), 174 with monoclonal gammopathy of undetermined significance (MGUS), and 34 with other forms (excluding amyloidosis). Univariable correlates of VTD were assessed using Kaplan–Meier analysis and Cox proportional hazards analysis. RESULTS The authors identified several univariable correlates of VTD in patients with MGUS, including a family and medical history of VTD, immobility, low serum albumin level, and high leukocyte count. Patients with MGUS with immunoglobulin (Ig) G monoclonal immunoglobulin were found to be less prone to develop VTD. In patients with MM, a family and medical history of VTD and the presence of a hypercoagulable state were factors identified in univariable analysis to be associated with an increased risk of VTD. In patients with MM, for each unit increase in serum albumin, the risk of VTD was lower. The type of the treatment regimen did not appear to correlate with the development of VTD. CONCLUSIONS In the current study, the risk for thromboembolic diseases among patients with PCD was increased compared with the risk in the general population. Further studies are necessary to define the mechanisms involved. Cancer 2004. © 2004 American Cancer Society.Keywords
This publication has 29 references indexed in Scilit:
- Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapyBlood, 2002
- Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapyBlood, 2002
- Actiated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complicationsBlood Coagulation & Fibrinolysis, 2002
- A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined SignificanceNew England Journal of Medicine, 2002
- Thromboembolism in Patients on Thalidomide for MyelomaHematology, 2002
- Age-Associated Increased Interleukin-6 Gene Expression, Late-Life Diseases, and FrailtyAnnual Review of Medicine, 2000
- Deep Vein Thrombosis as a Predictor of CancerAngiology, 1996
- Mutation in blood coagulation factor V associated with resistance to activated protein CNature, 1994
- Deep-Vein Thrombosis and the Incidence of Subsequent Symptomatic CancerNew England Journal of Medicine, 1992
- Abnormal Fibrin Ultrastructure, Polymerization, and Clot Retraction in Multiple Myeloma*British Journal of Haematology, 1970